Combined neuromodulatory interventions in acute experimental pain : assessment of melatonin and non-invasive brain stimulation
dc.contributor.author | Silva, Nadia Regina Jardim da | pt_BR |
dc.contributor.author | Laste, Gabriela | pt_BR |
dc.contributor.author | Deitos, Alícia | pt_BR |
dc.contributor.author | Stefani, Luciana Paula Cadore | pt_BR |
dc.contributor.author | Canto, Gustavo Cambraia do | pt_BR |
dc.contributor.author | Torres, Iraci Lucena da Silva | pt_BR |
dc.contributor.author | Brunoni, Andre Russowsky | pt_BR |
dc.contributor.author | Fregni, Felipe | pt_BR |
dc.contributor.author | Caumo, Wolnei | pt_BR |
dc.date.accessioned | 2019-01-16T04:09:52Z | pt_BR |
dc.date.issued | 2015 | pt_BR |
dc.identifier.issn | 1662-5153 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/187803 | pt_BR |
dc.description.abstract | Transcranial direct current stimulation (tDCS) and melatonin can effectively treat pain. Given their potentially complementary mechanisms of action, their combination could have a synergistic effect. Thus, we tested the hypothesis that compared to the control condition and melatonin alone, tDCS combined with melatonin would have a greater effect on pain modulatory effect, as assessed by quantitative sensory testing (QST) and by the pain level during the Conditioned Pain Modulation (CPM)-task. Furthermore, the combined treatment would have a greater cortical excitability effect as indicated by the transcranial magnetic stimulation (TMS) and on the serum BDNF level. Healthy males (n = 20), (aged 18–40 years), in a blinded, placebo-controlled, crossover, clinical trial, were randomized into three groups: sublingual melatonin (0.25 mg/kg) + a-tDCS, melatonin (0.25 mg/kg) + sham-(s)-tDCS, or sublingual placebo+sham-(s)- tDCS. Anodal stimulation (2 mA, 20 min) was applied over the primary motor cortex. There was a significant difference in the heat pain threshold ( C) for melatonin+a-tDCS vs. placebo+s-tDCS (mean difference: 4.86, 95% confidence interval [CI]: 0.9 to 8.63) and melatonin+s-tDCS vs. placebo+s-tDCS (mean: 5.16, 95% CI: 0.84 to 8.36). There was no difference between melatonin+s-tDCS and melatonin+a-tDCS (mean difference: 0.29, 95% CI: 3.72 to 4.23). The mean change from the baseline on amplitude of motor evocate potential (MEP) was significantly higher in the melatonin+a-tDCS (19.96% 5.2) compared with melatonin+s-tDCS group (1.36% 5.35) and with placebo+s-tDCS group (3.61% 10.48), respectively (p < 0.05 for both comparisons). While melatonin alone or combined with a-tDCS did not significantly affect CPM task result, and serum BDNF level. The melatonin effectively reduced pain; however, its association with a-tDCS did not present an additional modulatory effect on acute induced pain. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Frontiers in behavioral neuroscience. Lausanne. Vol. 9 (Mar. 2015), article 77, [12] p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | tDCS | en |
dc.subject | Estimulação magnética transcraniana | pt_BR |
dc.subject | TMS | en |
dc.subject | Limiar da dor | pt_BR |
dc.subject | CPM | en |
dc.subject | Melatonina | pt_BR |
dc.subject | Ensaio clínico | pt_BR |
dc.subject | Pain threshold | en |
dc.subject | Melatonin | en |
dc.subject | Clinical trial | en |
dc.title | Combined neuromodulatory interventions in acute experimental pain : assessment of melatonin and non-invasive brain stimulation | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 000956682 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
![](/themes/Mirage2Novo//images/lume/cc.png)
-
Artigos de Periódicos (39351)Ciências da Saúde (10587)
-
Artigos de Periódicos (39351)Ciências Biológicas (3068)